Journal of Gastrointestinal Cancer

, Volume 49, Issue 1, pp 9–15 | Cite as

Staging, Treatment, and Future Approaches of Gallbladder Carcinoma

  • Sanjeev Kumar Shukla
  • Govind SinghEmail author
  • K. S. Shahi
  • Bhuvan
  • Prabhat Pant
Review Article



Gallbladder cancer is the most common malignant cancer of the bile ducts and third most common gastrointestinal malignant in the world for public health. Its relatively low incidence and confused symptoms result in advanced disease at the time of presentation, contributing to poor prognosis and reduced survival associated with this disease. The main function of the gallbladder is to store excreted bile acids from the liver in preparation for a meal. Its main risk factor is prolonged exposure to biliary calculations, although bacterial infections and other inflammatory conditions are associated. Chronic inflammatory bowel conditions are associated with gallbladder cancer. T stage translates to identifying residual disease at reoperation for incidental gallbladder cancer and residual disease negatively affects survival.


It is the most common cancer of gallbladder, gallbladder cancer remains a rare disease. Gallbladder cancer is a rare disease that can be accidentally diagnosed after cholecystectomy or accidentally, often with more advanced disease. The prognosis is generally extremely poor and improvements in surgical resection of this approach have to be re-evaluated, while the role of chemotherapy and radiotherapy remains controversial.


Gallbladder Carcinoma Treatment Cholecystectomy Staging 



I thank the review studies of GBC of participants who contributed to this work and I appreciate the supporting staff of Multidisciplinary Research Unit (MRU). I am highly thankful to the Principal, of Government Medical College, Haldwani, Nainital, Uttarakhand, India for giving a research place for this work.

Funding Information

This study was funded by Department of Health and Research, New Delhi, India.

Compliance with Ethical Standards

Conflict of Interest

None of the authors of this paper have a financial or personal relationship with other people or organization that could inappropriately influence or bias the content of the paper.


  1. 1.
    Dutta U, Garg PK, Kumar R, Tandon RK. Typhoid carriers among patients with gallstones are at increased risk for carcinoma of the gallbladder. Am J Gastroenterol. 2000;95(3):784–7. Scholar
  2. 2.
    Larsson SC, Kansson NH, Wolk A. Healthy dietary patterns and incidence of biliary tract and gallbladder cancer in a prospective study of women and men. Eur J Cancer. 2017;70:42–7. Scholar
  3. 3.
    Agarwal AK, Javed A, Kalayarasan R, Sakhuja P. Minimally invasive versus the conventional open surgical approach of a radical cholecystectomy for gallbladder cancer: a retrospective comparative study. HPB (Oxford). 2015;17(6):536–41. Scholar
  4. 4.
    Destoll M. Rationis mendendi. In: Haak et Socios A et J Honkoop, editor. Nosocomio practico vendobonensi, Part I. Lugduni Batavorum; 1788Google Scholar
  5. 5.
    DeRegato JA, Spjut HJ. Digestive tract/accessory organo gallbladder. In: Ackerman LV, JA DR, editors. Cancer—diagnosis, treatment and prognosis. 5th ed. St Louis: CV Mosby; 1977. p. 599–604.Google Scholar
  6. 6.
    Medina E. Las enfermedades digestivas en Chile, panorama epidemiologico. Revista Medica De Chile. 1988;116(3):282–8.PubMedGoogle Scholar
  7. 7.
    Moertel CG. The gallbladder. In: Holland JF, Frei III E, editors. Cancer medicine. 2nd ed. Philadelphia: Lea Ferbiger; 1982. 1782–1785.Google Scholar
  8. 8.
    Shen HX, Song HW, Xu XJ, Jiao ZY, Ti ZY, Li ZY, et al. Clinical epidemiological survey of gallbladder carcinoma in northwestern China. 2009-2013: 2379 cases in 17 centers. Chronic Dis Trans Med. 2017;3(1):60–6. Scholar
  9. 9.
    Izarzugaza MI, Fernandez L, Forman D, Sierra MS. Burden of gallbladder cancer in Central and South America. Cancer Epidemiol. 2016;44:82–9.CrossRefGoogle Scholar
  10. 10.
    Goetze TO. Gallbladder carcinoma: prognostic factors and therapeutic options. World J Gastroenterol. 2015;21(43):12211–7. Scholar
  11. 11.
    Randi G, Malvezzi M, Levi F, Ferlay J, Negri E, Franceschi S, et al. Epidemiology of biliary tract cancers: an update. Ann Oncol. 2009;20:146–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Donohue JH, Nagorney DM, Grant CS, Tsushima K, Ilstrup DM, Adson MA. Carcinoma of the gallbladder: does radical resection improve outcome. Arch Surg. 1990;125(2):237–41. Scholar
  13. 13.
    Gourgiotis S, Oikonomou C, Kollia P, Falidas E, Villias C. Persistent coughing as the first symptom of primary mucinous appendiceal adenocarcinoma. J Clin Med Res. 2015;7(8):649–52. Scholar
  14. 14.
    Sobin LH, Wittekind C. Digestive system: gallbladder. In: TNM classification of malignant tumours. 6th ed. New York: Wiley-Liss; 2002. p. 84–6.Google Scholar
  15. 15.
    Qadan M, Kingham TP. Technical aspects of gallbladder cancer surgery. Surg Clin North Am. 2016;96(2):229–45. Scholar
  16. 16.
    Nevin JE, Moran TJ, Kay S, King R. Carcinoma of the gallbladder: staging, treatment and prognosis. Cancer. 1976;37(1):141–8.<141::AID-CNCR2820370121>3.0.CO;2-Y.CrossRefPubMedGoogle Scholar
  17. 17.
    Albores-Saavedra J, Henson DE, Sobin LH. The WHO histological classification of tumours of the gallbladder and extra hepatic bile duct a commentary on the second edition. Cancer. 1992;70(2):410–4.<410::AID-CNCR2820700207>3.0.CO;2-R.CrossRefPubMedGoogle Scholar
  18. 18.
    Everhart JE, Khare M, Hill M, Maurer KR. Prevalence and ethnic differences in gallbladder disease in the United States. Gastroenterol. 1999;117(3):632–9. Scholar
  19. 19.
    Venneman NG, VanErpecum KJ. Pathogenesis of gallstones. Gastroenterol Clin N Am. 2010;39(2):171–83. Scholar
  20. 20.
    Carriaga M, Henson DE. Liver, gallbladder, extra hepatic bile ducts and pancreas. Cancer. 1995;75(S1):171–90.<171::AID-CNCR2820751306>3.0.CO;2-2.CrossRefPubMedGoogle Scholar
  21. 21.
    Pilgrim CH, Groeschl RT, Christians KK, Gamblin TC. Modern perspectives on factors predisposing to the development of gallbladder cancer. HPB (Oxford). 2013;15(11):839–44. Scholar
  22. 22.
    Sharma V, Chauhan VS, Nath G, Kumar A, Shukla VK. Role of bacteria in gallbladder carcinoma. Hepato-Gastroenterology. 2007;54(78):1622–5.PubMedGoogle Scholar
  23. 23.
    Rai R, Sharma KL, Misra S, Kumar A, Mittal B. PSCA gene variants (rs2294008 and rs2978974) confer increased susceptibility of gallbladder carcinoma in females. Gene. 2013;530(2):172–7. Scholar
  24. 24.
    Maharaj R, Cave C, Sarran K, Bascombe N, Dan D, Greaves W, et al. A case report of the clear cell variant of gallbladder carcinoma. Int J Surg Case Rep. 2017;32:36–9. Scholar
  25. 25.
    Sampliner RE, Bennett PH, Comers LJ, Rose FA, Burch TA. Gallbladder disease in Pima Indians demonstration of high prevalence and early onset by cholecystography. N Engl J Med. 1970;283(25):1358–64. Scholar
  26. 26.
    Cetta F. The role of bacteria in pigment gallstones disease. Ann Surg. 1991;231:315–26.CrossRefGoogle Scholar
  27. 27.
    Landgren AM, Landgren O, Gridley G, Dores GM, Linet MS, Morton LM. Autoimmune disease and subsequent risk of developing alimentary tract cancers among 45 million US male veterans. Cancer. 2011;117(6):1163–71. Scholar
  28. 28.
    Koshiol J, Lam TK, Gridley G, Check D, Brown LM, Landgren O. Racial differences in chronic immune stimulatory conditions and risk of non-Hodgkin’s lymphoma in veterans from the United States. J Clin Oncol. 2011;29(4):378–85. Scholar
  29. 29.
    Castro FA, Liu X, Forsti A, Ji J, Sundquist J, Sundquist K, et al. Increased risk of hepatobiliary cancers after hospitalization for autoimmune disease. Clin Gastroenterol Hepatol. 2014;12(6):1038–45. Scholar
  30. 30.
    Shukla VK, Shukla PK, Pandey M, Rao BR, Salil KR. Lipid peroxidation product in bile from patients with carcinoma of the gallbladder: a preliminary study. J Surg Oncol. 1994;56(4):258–62. Scholar
  31. 31.
    Pandey M, Shukla VK. Fatty acids, biliary bile acids, lipid peroxidation products and gallbladder carcinogenesis. Eur J Cancer Prev. 2000;9(3):165–71. Scholar
  32. 32.
    Kuzmickiene I, Didziapetris R, Stukonis M. Cancer incidence in the workers cohort of textile manufacturing factory in Alytus, Lithuania. J Occup Environ Med. 2004;46(2):147–53. Scholar
  33. 33.
    Lazcano-Ponce EC, Miquel JF, Munoz N, Herrero R, Ferrecio C, Wistuba II, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2001;51(6):349–64. Scholar
  34. 34.
    Sumiyoshi K, Nagai E, Chijiiwa K, Nakayama F. Pathology of carcinoma of the gallbladder. World J Surg. 1991;15(3):315–21. Scholar
  35. 35.
    Kim YT, Kim J, Jang YH, Lee WJ, Ryu JK, Park YK, et al. Genetic alterations in gallbladder adenoma, dysplasia and carcinoma. Cancer Lett. 2001;169(1):59–68. Scholar
  36. 36.
    Wistuba II, Sugio K, Hung J, Kishimoto Y, Virmani AK, Roa I, et al. Allele-specific mutations involved in the pathogenesis of endemic gallbladder carcinoma in Chile. Cancer Res. 1995;55(12):2511–5.PubMedGoogle Scholar
  37. 37.
    Lee DK, Tarr PI, Haigh WG, Lee SP, Bacterial DNA. In mixed cholesterol gallstones. Am J Gastroenterol. 1999;94(12):3502–6. Scholar
  38. 38.
    Vassella E, Langsch S, Dettmer MS, Schlup C, Neuenschwander M, Frattini M, et al. Molecular profiling of lung adenosquamous carcinoma: hybrid orgenuine type. Oncotarget. 2015;6(27):23905–16. Scholar
  39. 39.
    Lin LL, Picus J, Drebin JA, Linehan DC, Solis J, Strasberg SM, et al. A phase II study of alternating cycles of split course radiation therapy and gemcitabine chemotherapy for inoperable pancreatic or biliary tract carcinoma. Am J Clin Oncol. 2005;28(3):234–41. Scholar
  40. 40.
    Ammori JB, Colletti LM, Zalupski MM, Eckhauser FE, Greenson JK, Dimick J, et al. Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J Gastrointest Surg. 2003;7(6):766–72. Scholar
  41. 41.
    Kaneoka Y, Yamaguchi A, Isogai M, Harada T, Suzuki M. Hepatoduodenal ligament invasion by gallbladder carcinoma: histologic patterns and surgical recommendation. World J Surg. 2003;27(3):260–5. Scholar
  42. 42.
    Prior IA, Lewis PD, Mattos CA. Comprehensive survey of Ras mutations in cancer. Cancer Res. 2012;72(10):2457–67. Scholar
  43. 43.
    Gupta P, Agarwal A, Gupta V, Singh PK, Pantola C, Amit S. Expression and clinicopathological significance of estrogen and progesterone receptors in gallbladder cancer. Gastrointest Cancer Res. 2012;5(2):41–7.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Sherr CT, McCormick F. The RB and p53 pathways in cancer. Cancer Cell. 2002;2(2):103–12. Scholar
  45. 45.
    Doval D, Prabhash K, Patil S, Chaturvedi H, Goswami C, Vaid A, et al. Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung. Onco Targets Ther. 2015;8:117–23. Scholar
  46. 46.
    Xuan YH, Choi YL, Shin YK, Kook MC, Chae SW, Park SM, et al. An immunohistochemical study of the expression of cell-cycle-regulated proteins p53, cyclin D1, RB, p27, Ki67 and MSH2 in gallbladder carcinoma and its precursor lesions. Histol Histopathol. 2005;20(1):59–66. Scholar
  47. 47.
    Maurya SK, Tewari M, Mishra RR, Shukla HS. Genetic aberrations in gallbladder cancer. Surg Oncol. 2012;21(1):37–43. Scholar
  48. 48.
    Moy AP, Shahid M, Ferrone CR, Borger DR, Zhu AX, Ting D, et al. Microsatellite instability in gallbladder carcinoma. Virchows Arch. 2015;466(4):393–402. Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2017

Authors and Affiliations

  • Sanjeev Kumar Shukla
    • 1
  • Govind Singh
    • 2
    Email author
  • K. S. Shahi
    • 3
  • Bhuvan
    • 3
  • Prabhat Pant
    • 4
  1. 1.Multidisciplinary Research UnitGovernment Medical CollegeNainitalIndia
  2. 2.Department of BiochemistryGovernment Medical CollegeNainitalIndia
  3. 3.Department of SurgeryGovernment Medical CollegeNainitalIndia
  4. 4.Department of PathologyGovernment Medical CollegeNainitalIndia

Personalised recommendations